Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia Pharma (TSE:4579) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
RaQualia Pharma Forward PE Ratio Related Terms
RaQualia Pharma Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma Forward PE Ratio Chart
RaQualia Pharma Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
14.67
21.01
RaQualia Pharma Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
14.67
14.90
20.61
11.98
21.01
17.13
TSE:4579 vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, RaQualia Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
RaQualia Pharma (TSE:4579) has a Forward PE Ratio of 10.21 as of Aug. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #90 out of 354 companies in the Biotechnology industry, placing it in the top 25.4%.
Is RaQualia Pharma's Forward PE Ratio too high?
RaQualia Pharma's current Forward PE Ratio is 10.21. The Biotechnology industry median Forward PE Ratio is 22.29. RaQualia Pharma's value of 10.21 is 54.2% below this industry median. Based on the distribution chart, RaQualia Pharma ranks #90 out of 354 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #90 out of 354 companies for Forward PE Ratio. This puts RaQualia Pharma in the upper half of its industry. The industry median Forward PE Ratio is 22.29. RaQualia Pharma's value of 10.21 is 54.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.29, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Forward PE Ratio of 10.21 is 54.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Forward PE Ratio is 10.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円311.26, compared to a current price of 円494.00 — trading 58.7% above its estimated fair value. The current Forward PE Ratio is 10.21 and 54.2% below the Biotechnology industry median of 22.29. RaQualia Pharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Forward PE Ratio is 10.21 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円494.00 is trading 58.7% above its estimated GF Value™ of 円311.26.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
Forward PE Ratio: 10.21
GF Value™: 円311.26 vs. price of 円494.00 (58.7% above fair value)
Industry Position: 54.2% below the Biotechnology median (#90 of 354)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
